Growth

Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.

Every part of health care today needs connectivity, says Cisco’s Troy Yoder. He explaines the unique role the company’s technology plays in ensuring patients get the best care the medtech industry can offer.

A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.

In Vivo editorial advisory board member and ZS principal Brian Chapman identifies the agenda-topping themes for medtech bosses.

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.

The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.